Skip to content
2000
Volume 26, Issue 1
  • ISSN: 1871-5303
  • E-ISSN: 2212-3873
file format text download EPUB
file format pdf download PDF
side by side viewer icon HTML

Abstract

SGLT2 inhibitors are a family of drugs that were developed to treat diabetes mellitus. In randomized controlled trials, SGLT2 inhibitors seem to prevent kidney deterioration in patients with nephropathies, both diabetic and non-diabetic. However, in contrast to biochemical/physiological results (proteinuria and serum creatinine levels) that improve in all studies, the clinical results (all-cause mortality, cardiovascular death, need for dialysis, or renal transplant) do not consistently improve. In this article, the author would like to suggest that SGLT2 inhibitors do not, in fact, prevent the progression of renal diseases but rather alter laboratory results. This study will present a theory that gives an alternative explanation for the findings in the studies that would explain the above discrepancy between biochemical/physiological and clinical results. In general, the author claims that SGLT2 inhibitors change the kinetics of renal creatinine and microalbumin excretion but do not prevent parenchymal adverse changes in kidneys. This causes a dissociation between renal function markers (such as serum creatinine level and urinary protein) and the real kidney function. Thus, the clinical renal prognosis does not improve despite seemingly better laboratory results.

© 2026 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303355221241021050443
2026-01-01
2026-02-16

  • From This Site

    /content/journals/emiddt/10.2174/0118715303355221241021050443
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/emiddt/26/1/EMIDDT-26-E18715303355221.html?itemId=/content/journals/emiddt/10.2174/0118715303355221241021050443&mimeType=html&fmt=ahah

References

  1. MussoG. GambinoR. CassaderM. PaganoG. A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials.Ann. Med.201244437539310.3109/07853890.2011.56018121495788
     [Google Scholar]
  2. BraunwaldE. Gliflozins in the management of cardiovascular disease.N. Engl. J. Med.2022386212024203410.1056/NEJMra211501135613023
     [Google Scholar]
  3. SeiduS. AlabrabaV. DaviesS. Newland-JonesP. FernandoK. BainS.C. DiggleJ. EvansM. JamesJ. KanumilliN. MilneN. ViljoenA. WheelerD.C. WildingJ.P.H. SGLT2 inhibitors – the new standard of care for cardiovascular, renal and metabolic protection in type 2 Diabetes: A narrative review.Diabetes Ther.20241551099112410.1007/s13300‑024‑01550‑538578397
     [Google Scholar]
  4. OlanrewajuO.A. SheebaF. KumarA. AhmadS. BlankN. KumariR. KumariK. SalameT. KhalidA. yousefN. VarrassiG. KhatriM. KumarS. MohamadT. Novel therapies in Diabetes: A comprehensive narrative review of glp-1 receptor agonists, sglt2 inhibitors, and beyond.Cureus20231512e5115110.7759/cureus.5115138283440
     [Google Scholar]
  5. WiviottS.D. RazI. BonacaM.P. MosenzonO. KatoE.T. CahnA. SilvermanM.G. ZelnikerT.A. KuderJ.F. MurphyS.A. BhattD.L. LeiterL.A. McGuireD.K. WildingJ.P.H. RuffC.T. Gause-NilssonI.A.M. FredrikssonM. JohanssonP.A. LangkildeA.M. SabatineM.S. Dapagliflozin and cardiovascular outcomes in type 2 Diabetes.N. Engl. J. Med.2019380434735710.1056/NEJMoa181238930415602
     [Google Scholar]
  6. NealB. PerkovicV. MahaffeyK.W. de ZeeuwD. FulcherG. EronduN. ShawW. LawG. DesaiM. MatthewsD.R. Canagliflozin and cardiovascular and renal events in type 2 Diabetes.N. Engl. J. Med.2017377764465710.1056/NEJMoa161192528605608
     [Google Scholar]
  7. ZinmanB. WannerC. LachinJ.M. FitchettD. BluhmkiE. HantelS. MattheusM. DevinsT. JohansenO.E. WoerleH.J. BroedlU.C. InzucchiS.E. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 Diabetes.N. Engl. J. Med.2015373222117212810.1056/NEJMoa150472026378978
     [Google Scholar]
  8. HeerspinkH.J.L. StefánssonB.V. Correa-RotterR. ChertowG.M. GreeneT. HouF.F. MannJ.F.E. McMurrayJ.J.V. LindbergM. RossingP. SjöströmC.D. TotoR.D. LangkildeA.M. WheelerD.C. Dapagliflozin in patients with chronic kidney disease.N. Engl. J. Med.2020383151436144610.1056/NEJMoa202481632970396
     [Google Scholar]
  9. HeerspinkH.J.L. SjöströmC.D. JongsN. ChertowG.M. KosiborodM. HouF.F. McMurrayJ.J.V. RossingP. Correa-RotterR. KurlyandskayaR. StefanssonB.V. TotoR.D. LangkildeA.M. WheelerD.C. HeerspinkH.J.L. WheelerD.C. ChertowG. Correa-RotterR. GreeneT. Fan HouF. McMurrayJ. RossingP. TotoR. StefanssonB. Maria LangkildeA. MaffeiL.E. RaffaeleP. SolisS.E. AriasC.A. AizenbergD. LuquezC. ZaidmanC. CluigtN. MayerM. AlvarisquetaA. WassermannA. MaldonadoR. BittarJ. MaurichM. GaiteL.E. GarciaN. SivakL. RamalloP.O. SantosJ.C. Garcia DuranR. OddinoJ.A. MaranonA. MaiaL.N. D AvilaD. BarrosE.J.G. VidottiM.H. PanarottoD. NoronhaI.D.L. TurattiL A A. DeboniL. CanzianiM.E. RiellaM.C. BacciM.R. PaschoalinR.P. FrancoR.J. GoldaniJ.C. St-AmourE. SteeleA.W. GoldenbergR. PandeyaS. BajajH. CherneyD. KaiserS.M. ConwayJ.R. ChowS.S. BaileyG. LafranceJ. WintersteinJ. CournoyerS. GaudetD. MadoreF. HouldenR.L. DowellA. LangloisM. MuirheadN. KhandwalaH. LevinA. HouF. XueY. ZuoL. HaoC. NiZ. XingC. ChenN. DongY. ZhouR. XiaoX. ZouY. WangC. LiuB. ChenQ. LinM. LuoQ. ZhangD. WangJ. ChenM. WangX. ZhongA. DongJ. ZhuC. YanT. LuoP. RenY. PaiP. LiD. ZhangR. ZhangJ. XuM. ZhuangY. KongY. YaoX. PengX. PerssonF.I. HansenT.K. BorgR. Pedersen BjergaardU. HansenD. HornumM. HallerH. KlausmannG. TschopeD. KrugerT. GrossP. HugoC. ObermullerN. RoseL. MertensP. Zeller-StefanH. FritscheA. RendersL. MullerJ. BuddeK. SchroppelB. WittmannI. VorosP. DudasM. TabakG.A. KirschnerR. LetohaA. BalkuI. HermanyiZ. ZakarG. MezeiI. NagyG.G. LippaiJ. NemethA. KhullarD. GowdaiahP.K. Fernando MervinE. RaoV.A. DewanD. MaddiV.S.K. VyawahareM.S. PulichikkatR.K. SonkarS.K. GuptaV.K. AgarwalS. AsirvathamA.J. IgnatiusA. ChaubeyS. MelemadathilS. AlvaH. KadamY. ShimizuH. SueyoshiA. TakeokaH. AbeY. ImaiT. OnishiY. FujitaY. TokitaY. MakitaY. IdogakiA. KoyamaR. KikuchiH. KashiharaN. HayashiT. AndoY. TanakaT. ShimizuM. HidakaS. GohdaT. TamuraK. AbeM. KamijoY. ImasawaT. TakahashiY. NakayamaM. TomitaM. HiranoF. NakayamaM. FukushimaY. KiyosueA. KuriokaS. ImaiE. KitagawaK. WakiM. WadaJ. UeharaK. IwataniH. OtaK. ShibazakiS. TamuraK. KatayamaK. NaritaI. IinumaM. MatsuedaS. SasakiS. YokochiA. TsukamotoT. YoshimuraT. KangS. LeeS. LimC.S. ChinH. JooK.W. HanS.Y. ChangT.I. ParkS. ParkH. ParkC.W. HanB.G. ChaD.R. YoonS.A. KimW. KimS.W. RyuD. Correa RotterR. Irizar SantanaS.S. Hernandez LlamasG. Valdez OrtizR. Secchi NicolasN.C. Gonzalez GalvezG. Lazcano SotoJ.R. Bochicchio RiccardelliT. Bayram LlamasE.A. Ramos IbarraD.R. MeloM.G.S. Gonzalez GonzalezJ.G. Sanchez MijangosJ.H. Madero RobaloM. Garcia CastilloA. ManriqueH.A. FarfanJ.C. VargasR. ValdiviaA. DextreA. EscuderoE. Calderon TiconaJ.R. GonzalesL. VillenaJ. LeonL. MolinaG. SaavedraA. GarridoE. ArbanilH. Vargas MarquezS. RodriguezJ. IsidtoR. VillaflorA.J. GumbaM.A. TiradorL. ComiaR.S. SyR.A. GuanzonM.L.V.V. AquitaniaG. De AsisN.C. SilvaA.A. LimM.E. DanguilanR.A. NowickiM. RudzkiH. LandaK. Kucharczyk-BaumanI. Gogola-MigdalB. GolskiM. Olech-CudzikA. StomporT. SzczepanikT. MiklaszewiczB. SciborskiR. KuzniewskiM. CiechanowskiK. WronskaD. KlatkoW. MazurS. PopendaG. MyslickiM. BolievaL.Z. BernsS. GalyavichA. AbissovaT. KarpovaI. PlatonovD. KoziolovaN. KvitkovaL. NilkR. MedinaT. RebrovA. RossovskayaM. SinitsinaI. VishnevaE. ZagidullinN. NovikovaT. KrasnopeevaN. MagnitskayaO. AntropenkoN. BatiushinM. Escudero QuesadaV. Barrios BarreaC. Espinel GarauzE. Cruzado GarritJ.M. Morales PortilloC. Gorriz TeruelJ.L. Cigarran GuldrisS. Praga TerenteM. Robles Perez-MonteolivaN.R. Infanta CristinaH. Tinahones MaduenoF.J. Soto GonzalezA. Diaz RodriguezC. FurulandH. SaeedA. DrejaK. SpaakJ. BruchfeldA. KolesnykM. LevchenkoO. PyvovarovaN. StusV. DoretskyyV. KorobovaN. HoroshkoO. KaterenchukI. MostovoyY.M. OrynchakM. LegunO. DudarI. BilchenkoO. AndreychynS. LevchenkoA. ZubL. TereshchenkoN. TopchiiI. OstapenkoT. BezuglovaS. KopytsyaM. TurenkoO. MarkP. BarrattJ. BhandariS. FraserD. KalraP. KonS.P. MccaffertyK. MikhailA. KonS.P. AlvaradoO.P. AndersonR. AndrawisN.S. ArifA. BenjaminS.A. BuesoG. BuschR.S. CarrK.W. CarrK.W. CrawfordP. DaboulN. De La CalleG.M. DelgadoB. EarlJ. El-ShahawyM.A. GrafR.J. GreenwoodG. GuevaraA. WendlandE.M. MayfieldR.K. MonteroM. MorinD.J. NarayanP. NumrungroadV. ReddyA.C. ReddyR. SamsonM.B. TrejoR. ButcherM.B. WiseJ.K. ZemelL.R. RaikhelM. WeinsteinD. HernandezP. WynneA. KhanB.V. SterbaG.A. JamalA. RossD. RovnerS.F. TanA. OvalleF. PatelR.J. TalanoJ. PatelD.R. BurgnerA. AslamN. ElliottM. GoralS. JovanovichA. UmanathK. WaguespackD. WeinerD. YuM. SchneiderL. LeT. DT. NguyenN. NguyenH. NguyenD. NguyenV. DoT. ChuP. TaD. TranN. NguyenD. PfefferM.A. PocockS. SwedbergK. RouleauJ.L. ChaturvediN. IvanovichP. LeveyA.S. HeldC. ChristerssonC. MannJ. VarenhorstC. Effects of dapagliflozin on mortality in patients with chronic kidney disease: A pre-specified analysis from the DAPA-CKD randomized controlled trial.Eur. Heart J.202142131216122710.1093/eurheartj/ehab09433792669
     [Google Scholar]
  10. MosenzonO. WiviottS.D. CahnA. RozenbergA. YanuvI. GoodrichE.L. MurphyS.A. HeerspinkH.J.L. ZelnikerT.A. DwyerJ.P. BhattD.L. LeiterL.A. McGuireD.K. WildingJ.P.H. KatoE.T. Gause-NilssonI.A.M. FredrikssonM. JohanssonP.A. LangkildeA.M. SabatineM.S. RazI. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: An analysis from the DECLARE–TIMI 58 randomised trial.Lancet Diabetes Endocrinol.20197860661710.1016/S2213‑8587(19)30180‑931196815
     [Google Scholar]
  11. PerkovicV. de ZeeuwD. MahaffeyK.W. FulcherG. EronduN. ShawW. BarrettT.D. Weidner-WellsM. DengH. MatthewsD.R. NealB. Canagliflozin and renal outcomes in type 2 diabetes: Results from the CANVAS Program randomised clinical trials.Lancet Diabetes Endocrinol.20186969170410.1016/S2213‑8587(18)30141‑429937267
     [Google Scholar]
  12. PerkovicV. JardineM.J. NealB. BompointS. HeerspinkH.J.L. CharytanD.M. EdwardsR. AgarwalR. BakrisG. BullS. CannonC.P. CapuanoG. ChuP.L. de ZeeuwD. GreeneT. LevinA. PollockC. WheelerD.C. YavinY. ZhangH. ZinmanB. MeiningerG. BrennerB.M. MahaffeyK.W. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.N. Engl. J. Med.2019380242295230610.1056/NEJMoa181174430990260
     [Google Scholar]
  13. BhattD.L. SzarekM. PittB. CannonC.P. LeiterL.A. McGuireD.K. LewisJ.B. RiddleM.C. InzucchiS.E. KosiborodM.N. CherneyD.Z.I. DwyerJ.P. SciricaB.M. BaileyC.J. DíazR. RayK.K. UdellJ.A. LopesR.D. LapuertaP. StegP.G. Sotagliflozin in patients with diabetes and chronic kidney disease.N. Engl. J. Med.2021384212913910.1056/NEJMoa203018633200891
     [Google Scholar]
  14. CannonC.P. PratleyR. Dagogo-JackS. MancusoJ. HuyckS. MasiukiewiczU. CharbonnelB. FrederichR. GalloS. CosentinoF. ShihW.J. GantzI. TerraS.G. CherneyD.Z.I. McGuireD.K. Cardiovascular outcomes with ertugliflozin in type 2 diabetes.N. Engl. J. Med.2020383151425143510.1056/NEJMoa200496732966714
     [Google Scholar]
  15. WannerC. InzucchiS.E. LachinJ.M. FitchettD. von EynattenM. MattheusM. JohansenO.E. WoerleH.J. BroedlU.C. ZinmanB. Empagliflozin and progression of kidney disease in type 2 Diabetes.N. Engl. J. Med.2016375432333410.1056/NEJMoa151592027299675
     [Google Scholar]
  16. AnkerS.D. ButlerJ. FilippatosG. FerreiraJ.P. BocchiE. BöhmM. Brunner-La RoccaH.P. ChoiD.J. ChopraV. Chuquiure-ValenzuelaE. GiannettiN. Gomez-MesaJ.E. JanssensS. JanuzziJ.L. Gonzalez-JuanateyJ.R. MerkelyB. NichollsS.J. PerroneS.V. PiñaI.L. PonikowskiP. SenniM. SimD. SpinarJ. SquireI. TaddeiS. TsutsuiH. VermaS. VinereanuD. ZhangJ. CarsonP. LamC.S.P. MarxN. ZellerC. SattarN. JamalW. SchnaidtS. SchneeJ.M. BrueckmannM. PocockS.J. ZannadF. PackerM. Empagliflozin in heart failure with a preserved ejection fraction.N. Engl. J. Med.2021385161451146110.1056/NEJMoa210703834449189
     [Google Scholar]
  17. PackerM. AnkerS.D. ButlerJ. FilippatosG. PocockS.J. CarsonP. JanuzziJ. VermaS. TsutsuiH. BrueckmannM. JamalW. KimuraK. SchneeJ. ZellerC. CottonD. BocchiE. BöhmM. ChoiD.J. ChopraV. ChuquiureE. GiannettiN. JanssensS. ZhangJ. Gonzalez JuanateyJ.R. KaulS. Brunner-La RoccaH.P. MerkelyB. NichollsS.J. PerroneS. PinaI. PonikowskiP. SattarN. SenniM. SerondeM.F. SpinarJ. SquireI. TaddeiS. WannerC. ZannadF. Cardiovascular and renal outcomes with empagliflozin in heart failure.N. Engl. J. Med.2020383151413142410.1056/NEJMoa202219032865377
     [Google Scholar]
  18. PackerM. ButlerJ. ZannadF. PocockS.J. FilippatosG. FerreiraJ.P. BrueckmannM. JamalW. ZellerC. WannerC. AnkerS.D. Empagliflozin and major renal outcomes in heart failure.N. Engl. J. Med.2021385161531153310.1056/NEJMc211241134449179
     [Google Scholar]
  19. HerringtonW.G. StaplinN. WannerC. GreenJ.B. HauskeS.J. EmbersonJ.R. PreissD. JudgeP. MayneK.J. NgS.Y.A. SammonsE. ZhuD. HillM. StevensW. WallendszusK. BrennerS. CheungA.K. LiuZ.H. LiJ. HooiL.S. LiuW. KadowakiT. NangakuM. LevinA. CherneyD. MaggioniA.P. PontremoliR. DeoR. GotoS. RosselloX. TuttleK.R. SteublD. PetriniM. MasseyD. EilbrachtJ. BrueckmannM. LandrayM.J. BaigentC. HaynesR. Empagliflozin in patients with chronic kidney disease.N. Engl. J. Med.2023388211712710.1056/NEJMoa220423336331190
     [Google Scholar]
  20. SolomonS.D. McMurrayJ.J.V. ClaggettB. de BoerR.A. DeMetsD. HernandezA.F. InzucchiS.E. KosiborodM.N. LamC.S.P. MartinezF. ShahS.J. DesaiA.S. JhundP.S. BelohlavekJ. ChiangC.E. BorleffsC.J.W. Comin-ColetJ. DobreanuD. DrozdzJ. FangJ.C. Alcocer-GambaM.A. Al HabeebW. HanY. Cabrera HonorioJ.W. JanssensS.P. KatovaT. KitakazeM. MerkelyB. O’MearaE. SaraivaJ.F.K. TereshchenkoS.N. ThiererJ. VaduganathanM. VardenyO. VermaS. PhamV.N. WilderängU. ZaozerskaN. BachusE. LindholmD. PeterssonM. LangkildeA.M. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.N. Engl. J. Med.2022387121089109810.1056/NEJMoa220628636027570
     [Google Scholar]
  21. PrandiF.R. BaroneL. LecisD. BelliM. SergiD. MiliteM. LerakisS. RomeoF. BarillàF. Biomolecular mechanisms of cardiorenal protection with sodium-glucose co-transporter 2 inhibitors.Biomolecules20221210134910.3390/biom1210134936291558
     [Google Scholar]
  22. WrightE.M. SGLT2 inhibitors: Physiology and pharmacology.Kidney36020212122027203710.34067/KID.000277202135419546
     [Google Scholar]
  23. OjhaU. ReyesL. EyengaF. OumbeD. WatkowskaJ. Saint-JacquesH. Diabetes, heart failure and beyond: Elucidating the cardioprotective mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) inhibitors.Am. J. Cardiovasc. Drugs2022221354610.1007/s40256‑021‑00486‑634189716
     [Google Scholar]
  24. YauK. DhariaA. AlrowiytiI. CherneyD.Z.I. Prescribing SGLT2 inhibitors in patients with CKD: Expanding indications and practical considerations.Kidney Int. Rep.2022771463147610.1016/j.ekir.2022.04.09435812300
     [Google Scholar]
  25. DaviesM.J. ArodaV.R. CollinsB.S. GabbayR.A. GreenJ. MaruthurN.M. RosasS.E. Del PratoS. MathieuC. MingroneG. RossingP. TankovaT. TsapasA. BuseJ.B. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Diabetologia202265121925196610.1007/s00125‑022‑05787‑236151309
     [Google Scholar]
  26. HeidenreichP.A. BozkurtB. AguilarD. AllenL.A. ByunJ.J. ColvinM.M. DeswalA. DraznerM.H. DunlayS.M. EversL.R. FangJ.C. FedsonS.E. FonarowG.C. HayekS.S. HernandezA.F. KhazanieP. KittlesonM.M. LeeC.S. LinkM.S. MilanoC.A. NnachetaL.C. SandhuA.T. StevensonL.W. VardenyO. VestA.R. YancyC.W. 2022 AHA/ACC/HFSA guideline for the management of heart failure: Executive summary: A report of the american college of cardiology/american heart association joint committee on clinical practice guidelines.Circulation202214518e876e89410.1161/CIR.000000000000106235363500
     [Google Scholar]
  27. SheikhO. NashawiM. BattishaA. ChiltonR. A focused review of cardiovascular guideline related recommendations for the primary care physician in the USA.Cardiovasc. Endocrinol. Metab.202092364110.1097/XCE.000000000000019232537563
     [Google Scholar]
  28. StevensL.A. CoreshJ. GreeneT. LeveyA.S. Assessing kidney function--measured and estimated glomerular filtration rate.N. Engl. J. Med.2006354232473248310.1056/NEJMra05441516760447
     [Google Scholar]
  29. MussoC.G. MichelángeloH. VilasM. MartinezB. BonettoA. JaureguiR. AlgranatiL. Renal creatinine handling in very old patients with chronic renal disease.Int. Urol. Nephrol.201143389990210.1007/s11255‑010‑9886‑521190081
     [Google Scholar]
  30. DekkersC.C.J. SjöströmC.D. GreasleyP.J. CainV. BoultonD.W. HeerspinkH.J.L. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.Diabetes Obes. Metab.201921122667267310.1111/dom.1385531407856
     [Google Scholar]
  31. MordiN.A. MordiI.R. SinghJ.S. McCrimmonR.J. StruthersA.D. LangC.C. Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure.Circulation2020142181713172410.1161/CIRCULATIONAHA.120.04873932865004
     [Google Scholar]
  32. OshimaM. NeuenB.L. JardineM.J. BakrisG. EdwardsR. LevinA. MahaffeyK.W. NealB. PollockC. RosenthalN. WadaT. WheelerD.C. PerkovicV. HeerspinkH.J.L. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: A post-hoc analysis from the CREDENCE trial.Lancet Diabetes Endocrinol.202081190391410.1016/S2213‑8587(20)30300‑433065060
     [Google Scholar]
  33. PackerM. Hyperuricemia and gout reduction by SGLT2 inhibitors in diabetes and heart failure.J. Am. Coll. Cardiol.202483237138110.1016/j.jacc.2023.10.03038199714
     [Google Scholar]
  34. ChinoY. SamukawaY. SakaiS. NakaiY. YamaguchiJ. NakanishiT. TamaiI. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.Biopharm. Drug Dispos.201435739140410.1002/bdd.190925044127
     [Google Scholar]
  35. ShemeshO. GolbetzH. KrissJ.P. MyersB.D. Limitations of creatinine as a filtration marker in glomerulopathic patients.Kidney Int.198528583083810.1038/ki.1985.2052418254
     [Google Scholar]
  36. ChoosongsangP. SoonthornpunS. Overestimation of glomerular filtration rate calculated from creatinine as compared with cystatin C in patients with type 2 diabetes receiving sodium-glucose cotransportor 2 inhibitors.Diabet. Med.2022391e1465910.1111/dme.1465934309941
     [Google Scholar]
  37. van RuitenC.C. van der Aart-van der BeekA.B. IJzermanR.G. NieuwdorpM. HoogenbergK. van RaalteD.H. HeerspinkH.J.L. Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.Diabetes Obes. Metab.20212381851185810.1111/dom.1441033908691
     [Google Scholar]
  38. LeveyA.S. GansevoortR.T. CoreshJ. InkerL.A. HeerspinkH.L. GramsM.E. GreeneT. TighiouartH. MatsushitaK. BallewS.H. SangY. VoneshE. YingJ. ManleyT. de ZeeuwD. EckardtK.U. LevinA. PerkovicV. ZhangL. WillisK. Change in albuminuria and gfr as end points for clinical trials in early stages of ckd: A scientific workshop sponsored by the national kidney foundation in collaboration with the us food and drug administration and european medicines agency.Am. J. Kidney Dis.20207518410410.1053/j.ajkd.2019.06.00931473020
     [Google Scholar]
  39. AfkarianM. ZelnickL.R. HallY.N. HeagertyP.J. TuttleK. WeissN.S. de BoerI.H. Clinical manifestations of kidney disease among us adults with Diabetes, 1988-2014.JAMA2016316660261010.1001/jama.2016.1092427532915
     [Google Scholar]
  40. AnN. WuB. YangY. HuangZ. FengJ. Re-understanding and focusing on normoalbuminuric diabetic kidney disease.Front. Endocrinol. (Lausanne)202213107792910.3389/fendo.2022.107792936531487
     [Google Scholar]
  41. Sehtman-ShacharD.R. YanuvI. SchechterM. FishkinA. Aharon-HananelG. LeibowitzG. RozenbergA. MosenzonO. Normoalbuminuria-is it normal? The association of urinary albumin within the ‘normoalbuminuric’ range with adverse cardiovascular and mortality outcomes: A systematic review and meta‐analysis.Diabetes Obes. Metab.202426104225424010.1111/dom.1575239021242
     [Google Scholar]
  42. JongsN. GreeneT. ChertowG.M. McMurrayJ.J.V. LangkildeA.M. Correa-RotterR. RossingP. SjöströmC.D. StefanssonB.V. TotoR.D. WheelerD.C. HeerspinkH.J.L. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: A prespecified analysis from the DAPA-CKD trial.Lancet Diabetes Endocrinol.202191175576610.1016/S2213‑8587(21)00243‑634619106
     [Google Scholar]
  43. RoscioniS.S. Lambers HeerspinkH.J. de ZeeuwD. Microalbuminuria: Target for renoprotective therapy PRO.Kidney Int.2014861404910.1038/ki.2013.49024759154
     [Google Scholar]
  44. HeerspinkH.J.L. JongsN. ChertowG.M. LangkildeA.M. McMurrayJ.J.V. Correa-RotterR. RossingP. SjöströmC.D. StefanssonB.V. TotoR.D. WheelerD.C. GreeneT. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: A prespecified analysis from the DAPA-CKD trial.Lancet Diabetes Endocrinol.202191174375410.1016/S2213‑8587(21)00242‑434619108
     [Google Scholar]
  45. PollockC. StefánssonB. ReynerD. RossingP. SjöströmC.D. WheelerD.C. LangkildeA.M. HeerspinkH.J.L. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): A randomised, double-blind, placebo-controlled trial.Lancet Diabetes Endocrinol.20197642944110.1016/S2213‑8587(19)30086‑530992195
     [Google Scholar]
  46. WannerC. LachinJ.M. InzucchiS.E. FitchettD. MattheusM. GeorgeJ. WoerleH.J. BroedlU.C. von EynattenM. ZinmanB. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease.Circulation2018137211912910.1161/CIRCULATIONAHA.117.02826828904068
     [Google Scholar]
  47. PackerM. Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium–glucose cotransporter 2 inhibitors.Eur. Heart J.202344485027503510.1093/eurheartj/ehad23537086098
     [Google Scholar]
  48. DaugirdasJ.T. DepnerT.A. InrigJ. MehrotraR. RoccoM.V. SuriR.S. WeinerD.E. GreerN. IshaniA. MacDonaldR. OlsonC. RutksI. SlininY. WiltT.J. RoccoM. KramerH. ChoiM.J. Samaniego-PicotaM. ScheelP.J. WillisK. JosephJ. BreretonL. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update.Am. J. Kidney Dis.201566588493010.1053/j.ajkd.2015.07.01526498416
     [Google Scholar]
  49. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.Kidney Int. Suppl.201331150
     [Google Scholar]
/content/journals/emiddt/10.2174/0118715303355221241021050443
Loading
Do SGLT2 Inhibitors Protect the Kidneys? An Alternative Explanation
Endocr Metab Immune Disord Drug Targets 26, E18715303355221 (2026); https://doi.org/10.2174/0118715303355221241021050443
/content/journals/emiddt/10.2174/0118715303355221241021050443
/content/journals/emiddt/10.2174/0118715303355221241021050443
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Diabetes mellitus; microalbumin; neuropathy; proteinuria; renal failure; SGLT2

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test